MedTech Global Insights

In the final days of 2025, the US FDA made a pivotal change to how it evaluates medical devices, opening the door for Real-World Data (RWD) to take center stage in regulatory submissions. This episode breaks down what this policy shift means for the MedTech industry, moving beyond the traditional reliance on expensive clinical trials. We explore the immense opportunities this creates for faster, m...

Brazil has just opened a regulatory fast-track for AI medical devices, promising market approval in just 90 days. This is a massive opportunity for MedTech companies looking to expand into Latin America, but a hidden challenge is causing significant delays and unexpected costs for even the most prepared firms. This episode of MedTech Global Insights unpacks ANVISA's new resolution. We reveal the s...

Brazil's health authority, ANVISA, recently announced an exciting fast-track approval pathway for AI and machine learning medical software. This move promises to accelerate market access in one of Latin America's biggest markets, creating a massive opportunity for MedTech innovators worldwide. However, this golden opportunity comes with hidden complexities. The initial announcement lacks detailed...

Last week, the European Commission extended the challenging IVDR transition deadlines, giving diagnostic manufacturers more time. While this seems like a reprieve, it introduces significant strategic complexity and the dangerous risk of complacency. We dissect the new tiered deadlines and analyze what this major regulatory shift truly means for the global IVD market. This episode moves beyond the...

The European Commission has ended years of uncertainty by announcing a mandatory deadline for EUDAMED. As of May 28, 2026, medical device and IVD companies must comply with the database's core modules. This isn't just a new database; it's a new era of regulatory transparency that demands immediate and strategic action from everyone in the MedTech industry. This episode breaks down what the mandato...

This week, we unpack the major implications of the UK MHRA's landmark approval of GSK's new twice-yearly asthma treatment. This is more than a product launch; it's a crucial signal for the global MedTech industry on how to successfully navigate the complex and independent post-Brexit regulatory landscape. We explore why the UK is re-emerging as a viable, first-launch market for innovative devices....

Last week, the FDA unveiled a game-changing fast-track for AI diagnostics, but a hidden challenge is already causing chaos for unprepared companies. We break down the new 'Agile PMS' framework and what it means for your market access strategy. This new rule isn't just theory. We explore the real-world case of CardiaAI, a leading Boston-based startup that had its breakthrough product put on hold. T...

The US FDA is making its biggest change to quality system regulations in a generation, harmonizing with the global ISO 13485 standard. This shift, mandated by the new Quality Management System Regulation (QMSR), presents both opportunities for streamlined global compliance and significant hidden risks for unprepared manufacturers. Many global companies with existing ISO 13485 certification are ope...

The promise of AI in MedTech is undeniable, but a major regulatory storm is brewing in the European Union. A new, complex dual-compliance framework now requires AI-driven medical devices to satisfy both the rigorous Medical Device Regulation (MDR) and the brand-new EU AI Act. This episode of MedTech Global Insights dives deep into what this means for manufacturers, from startups to global enterpri...

The explosion of AI in MedTech is met with a tangled web of new global regulations. This week, we dissect the latest guidance from the IMDRF and explore the growing divide between regulatory bodies in the US, Europe, and beyond. For AI device makers, the path to market is now filled with more hidden risks than ever. We explore the critical case of "CardioClear AI," a company whose groundbreaking d...

In this episode of MedTech Global Insights, we dissect the FDA's newly finalized guidance on using Digital Health Technologies (DHTs) for remote data collection in clinical trials. This pivotal update opens the door for more decentralized and patient-centric studies but introduces stringent new requirements for verification, validation, and data integrity that will reshape how MedTech companies ap...

The European Union has rolled out tough new cybersecurity regulations for medical devices, forcing manufacturers to rethink their entire approach to product security. This episode dives into the practical challenges companies are facing, from securing legacy products to meeting intensive new documentation and surveillance demands. We explore the case of a German pacemaker manufacturer struggling t...

This week, we dive into a major regulatory challenge brewing in the European Union. MedTech Europe has officially called on the European Commission to resolve the long-standing conflict between the Medical Device Regulation (MDR) and the WEEE directive on electronic waste. This move could reshape compliance for any company selling electronic medical devices in the EU. We unpack how this regulatory...

The first week of December saw Artificial Intelligence take center stage in MedTech, but not always for the right reasons. While new systems promise to revolutionize patient triage in Greece and reduce physician burnout in the US, a more alarming trend has emerged. Major health insurers are now using AI to automatically deny patient claims, raising serious ethical and regulatory questions. This ep...

Last week, the US FDA's new digital health pilot program sent ripples through the MedTech industry. This is more than a simple regulatory update; it's a pivotal shift that moves cybersecurity from a compliance task to a major commercial and contractual battleground, fundamentally changing the rules for market access. This episode breaks down how the convergence of new FDA initiatives and proactive...

Traditional MedTech global expansion is broken, defined by premium consulting fees, opaque processes, and frustrating delays. This episode of MedTech Global Insights unpacks the new playbook for international market access, revealing how companies are finally breaking free from the old model. We explore how the strategic fusion of advanced AI and on-the-ground regulatory experts is revolutionizing...

In this episode of MedTech Global Insights, we tackle the silent killer of speed-to-market: regulatory documentation bottlenecks. As companies expand globally, the sheer volume and complexity of preparing submissions for different health authorities can lead to costly delays and divert expert teams to low-value administrative work. We explore how cutting-edge AI is transforming this landscape. Dis...

In the fast-paced world of MedTech, falling behind on regulatory changes isn't just a risk; it's a guarantee of costly delays and missed opportunities. The sheer volume of updates from global health authorities has made manual tracking an impossible task, leaving even the most diligent teams vulnerable to compliance gaps. This episode of MedTech Global Insights dives into the AI revolution in regu...

Are you ready to accelerate your MedTech or IVD product's global launch by 75%? In this episode of MedTech Global Insights, we explore how Pure Global's advanced AI platform is dismantling the traditional barriers to international market access, transforming a multi-year ordeal into a matter of months. We dive into how this technology provides real-time regulatory intelligence and automated compli...

In an industry where regulatory costs and complexities can stifle innovation, Pure Global's AI platform emerges as a game-changer. This episode of MedTech Global Insights delves into the five strategic advantages of leveraging their free, powerful AI agents to navigate the intricate world of global medical device registration. We explore how this technology isn't just an incremental improvement bu...

In this episode of MedTech Global Insights, we explore the number one hurdle for ambitious medical device and IVD companies: navigating the fragmented and complex world of international regulations. We unpack why the traditional, country-by-country approach to market entry is inefficient and costly in today's fast-paced environment. We then break down a modern, integrated strategy for global expan...

In this episode of MedTech Global Insights, we explore the paradigm shift in global market access strategy. We move beyond the traditional, fragmented approach of managing regulatory hurdles country by country and dive into the rise of integrated, technology-driven consulting firms. These firms are not just advisors; they are end-to-end partners with a clear mission to streamline global expansion....

Navigating the complex, ever-changing web of global MedTech regulations is a primary barrier to market entry. The traditional, manual approach is notoriously slow, costly, and fraught with risks of rejection, delaying access to critical innovations for patients worldwide. This episode of MedTech Global Insights explores a new, technology-driven paradigm. We dive into how embedding advanced AI and...

The global MedTech regulatory landscape is a maze of constantly changing rules and fragmented information. Relying on static guides or old webinars leads to costly delays and rejected submissions. This episode explores a modern solution: a "living library" of expert global insights that converts complex knowledge into simple, actionable checklists for your specific products and target markets. We...

Navigating the complex world of global MedTech regulations can be a major challenge. Many companies find themselves juggling multiple local consultants, leading to duplicated work, inconsistent strategies, and costly delays. This episode of MedTech Global Insights dives into the powerful alternative: partnering with a single, end-to-end provider for global market access. We explore how an integrat...